BioCorRx Granted Pre-IND Meeting with FDA for BICX101
BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the U.S. Food & Drug Administration (FDA) has granted a pre-IND meeting to the Company and it is scheduled to take place on Tuesday, September 19, 2017 in order to review the development plan to market BICX101, an injectable, sustained release naltrexone, for the treatment of opioid addiction and alcohol use disorders.
View full press release